ストックスクリーナーアプリを入手
506.57
0.71%
-2.99
前日終値:
$509.56
開ける：
$509.56
24時間の取引高:
49,481
Relative Volume:
0.08
時価総額：
$39.90B
収益：
$4.45B
当期純損益:
$1.10B
株価収益率:
37.27
EPS:
13.591
ネットキャッシュフロー:
$1.06B
1週間 パフォーマンス:
-2.75%
1か月 パフォーマンス:
-8.17%
6か月 パフォーマンス:
-11.83%
1年 パフォーマンス:
-21.44%
1日の値動き範囲:
$502.40
$509.56
1週間の範囲:
$500.61
$522.49
52週間の値動き範囲:
$500.61
$769.98
Idexx Laboratories Inc Stock (IDXX) Company Profile
名前
Idexx Laboratories Inc
セクター
電話
(207) 556-0300
住所
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX vs TMO, DHR, NTRA, IQV, A
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
506.52 | 39.76B | 4.45B | 1.10B | 1.06B | 13.59 |
TMO
Thermo Fisher Scientific Inc
|
627.88 | 225.48B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
206.64 | 140.70B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
340.61 | 47.41B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
269.95 | 43.09B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
149.13 | 41.42B | 7.23B | 1.41B | 1.09B | 4.979 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-15 | 開始されました | Citigroup | Neutral |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-10-31 | アップグレード | Stifel | Hold → Buy |
| 2025-10-01 | 開始されました | UBS | Neutral |
| 2025-08-05 | 繰り返されました | BTIG Research | Buy |
| 2025-07-01 | 開始されました | Jefferies | Buy |
| 2024-12-02 | 開始されました | Leerink Partners | Outperform |
| 2024-07-25 | 開始されました | BTIG Research | Buy |
| 2024-01-30 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | 開始されました | Exane BNP Paribas | Outperform |
| 2023-12-04 | アップグレード | Cleveland Research | Neutral → Buy |
| 2023-08-02 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | ダウングレード | Stifel | Buy → Hold |
| 2022-07-21 | アップグレード | Goldman | Neutral → Buy |
| 2022-07-12 | 開始されました | Piper Sandler | Overweight |
| 2022-05-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-02-08 | 開始されました | Atlantic Equities | Overweight |
| 2021-11-18 | 開始されました | Morgan Stanley | Overweight |
| 2021-08-05 | 再開されました | Credit Suisse | Outperform |
| 2021-07-12 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-02-17 | 開始されました | Barclays | Overweight |
| 2019-09-09 | 開始されました | Goldman | Neutral |
| 2019-05-23 | 開始されました | Guggenheim | Buy |
| 2018-11-02 | 繰り返されました | BofA/Merrill | Buy |
| 2018-05-07 | 繰り返されました | Stifel | Buy |
| 2018-01-16 | 開始されました | Piper Jaffray | Overweight |
| 2017-08-23 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | アップグレード | CL King | Neutral → Buy |
| 2017-02-03 | ダウングレード | Feltl & Co. | Hold → Sell |
| 2016-09-29 | 再開されました | BofA/Merrill | Neutral |
| 2016-08-16 | 繰り返されました | Stifel | Buy |
| 2016-08-03 | アップグレード | Northcoast | Sell → Neutral |
| 2016-07-20 | 繰り返されました | Canaccord Genuity | Buy |
| 2016-04-19 | 繰り返されました | Canaccord Genuity | Buy |
| 2016-04-01 | 開始されました | CL King | Neutral |
| 2016-03-21 | 繰り返されました | Stifel | Buy |
| 2016-02-04 | 開始されました | Credit Suisse | Outperform |
| 2015-10-29 | 繰り返されました | Stifel | Buy |
| 2015-08-28 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | 繰り返されました | Stifel | Buy |
| 2015-07-23 | 繰り返されました | Canaccord Genuity | Buy |
すべてを表示
Idexx Laboratories Inc (IDXX) 最新ニュース
IDXX - Finviz
IDEXX Laboratories stock gains as analysts lift targets - ad-hoc-news.de
IDEXX Laboratories Inc. stock underperforms Thursday when compared to competitors - MarketWatch
IDEXX Laboratories stock reacts to insider share sale and recent earnings strength - ad-hoc-news.de
Engaging In Options Activity, Lawrence D Kingsley Exercises Options Valued At $873K In IDEXX Laboratories - Benzinga
Insider Alert: IDEXX Director Lawrence Kingsley Sells $1.2 Million of Stock - The Motley Fool
Is IDEXX Laboratories Stock Underperforming the Dow? - inkl
Idexx Laboratories stock hits 52-week low at $517.00 By Investing.com - Investing.com Australia
IDEXX Laboratories (IDXX) director exercises options and sells 2,203 shares - Stock Titan
Idexx Laboratories stock hits 52-week low at $517.00 - investing.com
IDEXX Laboratories stock heads into the open after a modest gain - ad-hoc-news.de
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
IDEXX Laboratories stock holds near recent highs as diagnostics demand supports growth - ad-hoc-news.de
Down 16% in the Last 12 Months, Can IDEXX Stock Bounce Back in 2027? - TIKR.com
Veterinary Diagnostic Markets Report Now Available — See Exactly How IDEXX, Zoetis, Antech, Roche, and Thermo Fisher Are Positioned to Win Through 2030 - GlobeNewswire Inc.
IDEXX Laboratories, Inc. (IDXX) Stock Analysis: Exploring A 30% Upside Potential - DirectorsTalk Interviews
IDEXX Laboratories stock gains after strong Q2 results and raised 2026 outlook - ad-hoc-news.de
ETFs Investing in IDEXX Laboratories, Inc. Stocks - TradingView
IDXX: Idexx Laboratories Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
IDEXX Laboratories stock steadies after strong Q2 2026 results and raised outlook - AD HOC NEWS
IDEXX Laboratories stock holds firm as investors eye earnings history - ad-hoc-news.de
Idexx (IDXX) Down 7.8% Since Last Earnings Report: Can It Rebound? - Eastern Progress
IDEXX Laboratories Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
IDEXX Laboratories stock holds firm after earnings beat - AD HOC NEWS
Resilient IDEXX Laboratories stock holds above $550 as earnings beat supports guidance - AD HOC NEWS
IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference - Yahoo Finance
IDEXX Laboratories Inc. stock outperforms competitors despite losses on the day - MarketWatch
IDEXX Laboratories Inc. (IDXX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Are Wall Street Analysts Predicting IDEXX Laboratories Stock Will Climb or Sink? - webull.com
Insider Decision: Andrew Emerson Exercises Options At IDEXX Laboratories For $101K - Benzinga
IDEXX (NASDAQ: IDXX) CFO exercises 265 options at $178.26 - Stock Titan
IDEXX Laboratories stock holds high valuation as earnings outlook firms - Ad-hoc-news.de
Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now? - TradingView
IDEXX launches first dual-species point-of-care NT-proBNP test for cardiac disease in cats and dogs - DVM360
Rationale Behind Baron Focused Growth Fund’s IDEXX Laboratories (IDXX) Holding - Yahoo Finance
Flossbach Von Storch SE Invests $9.09 Million in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Danske Bank A S Buys New Stake in IDEXX Laboratories, Inc. $IDXX - MarketBeat
BofA Securities Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Raises Target Price to $665 - 富途牛牛
Resilient IDEXX Laboratories stock trades in the mid-$550s as investors weigh premium valuation and - Ad-hoc-news.de
IDXX (IDEXX Laboratories) Cash Flow from Operations : $1,372 Mil (TTM As of Jun. 2026) - GuruFocus
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
IDEXX Laboratories stock holds above the mid-$540s as valuation stays demanding - Ad-hoc-news.de
IDXX (IDEXX Laboratories) Cash From Discontinued Investing Activities : $0 Mil (TTM As of Jun. 2026) - GuruFocus
Tranche Update on IDEXX Laboratories, Inc.'s Equity Buyback Plan announced on August 13, 1999. - marketscreener.com
Plato Investment Management Ltd Takes $1.48 Million Position in IDEXX Laboratories, Inc. $IDXX - MarketBeat
IDEXX Labs Executing, But Valuation Continues To Weigh On That Execution (NASDAQ:IDXX) - Seeking Alpha
Weekly Recap: AI diagnostics expansion and Barclays trims target to $710 - TradingView
IDEXX Laboratories, Inc. (IDXX) Stock Analysis: Unpacking a 26.86% Potential Upside in the Diagnostics & Research Sector - DirectorsTalk Interviews
IDEXX Laboratories Inc (IDXX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Transamerica Large Core ESG's IDEXX Laboratories Inc(IDXX) Holding History - GuruFocus
Idexx Laboratories Inc (IDXX) 財務データ
収益
当期純利益
現金流量
EPS
1.51%
大文字化:
|
ボリューム (24 時間):